Google Cloud outlines design pattern for governed, high-compute biotech agents

Standard AI agents fail in biotechnology because drug discovery workflows involve sustained, stateful simulations that exceed typical timeout and context limits. To address this, Google Cloud proposes a decoupled architecture that separates the cognitive layer (reasoning) from the execution layer (compute), anchored by enterprise governance.

Separating Reasoning from Execution

The execution layer handles heavy lifting like protein folding and ligand screening using NVIDIA Inference Microservices (NIMs) deployed on Google Kubernetes Engine (GKE). These microservices run on NVIDIA G4 VMs with NVIDIA Blackwell GPUs. To mitigate cold-start latency, the pattern recommends maintaining active node pools and preloading model weights into VRAM. This setup allows teams to switch between public NVIDIA endpoints for prototyping and private VPC deployments for proprietary data without changing the agent's code.

Multi-Agent Orchestration

The cognitive layer uses a lead orchestrator and specialized sub-agents (e.g., Lead Optimization, Safety Screening) built on the Gemini platform. Key design choices include:

• In-process handoffs: Sub-agents communicate via in-memory calls rather than network APIs to reduce latency.
• Data offloading: Large structural files (PDB, trajectories) are stored in Cloud Storage, with only references passed to the LLM to preserve context windows.
• Specialized reasoning: General-purpose LLMs handle workflow logic, while domain-specific models like NVIDIA Nemotron handle biochemical reasoning to reduce hallucinations.

Governance and Autonomy

The Gemini platform provides built-in governance tools, including Model Armor for prompt injection defense and Agent Identity for audit trails. The pattern advocates for asymmetric autonomy: agents can autonomously perform reversible tasks like preliminary screens, but require human approval for irreversible actions such as advancing compounds to lab testing.